Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Angiotech acquires Haemacure assets

This article was originally published in The Gray Sheet

Executive Summary

Angiotech Pharmaceuticals says it will pursue commercialization of Haemacure's human biomaterial product candidates, namely fibrin sealant and thrombin hemostat, after acquiring the firm's assets in a deal announced April 7. Potential applications include general and abdominal surgery, cardiothoracic and vascular surgery, gynecology and urology surgery and reconstructive and plastic surgery. The U.S. surgical sealing and hemostat market is estimated at $500 million-plus annually, according to Angiotech. The asset sale has been authorized under Haemacure's Chapter 11 bankruptcy court proceedings. Angiotech provided Haemacure with a $2.5 million bridge loan last June, and estimates that, at closing, "it will have funded approximately $1.5 million in additional transaction-related expenses.

You may also be interested in...

Polish Industry Fighting Against Advertising Tax On Supplements

Advertising dietary supplements in Poland will incur a new tax under proposals from the country's Ministry of Health. While the government claims the motivation is to promote healthy eating choices, industry says supplements have been unfairly linked to poor dietary choices without evidence.

England’s NICE Future Proofs Approach To Using Data

UK HTA body NICE is looking to the future and rethinking its approach to data and how they inform its guidance.

Krka Responds To Romanian Allegations

Slovenia’s Krka has responded to media reports of “irregularities” at its Romanian subsidiary – including allegations of bribing local doctors to prescribe its products – by pledging to form a special investigation team to immediately examine the matter.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts